Arcturus Therapeutics (ARCT) Tops Q2 EPS by 38c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($0.64), $0.38 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $49.86 million versus the consensus estimate of $32.26 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• HSBC Raises S&P500 Target to 8,100
• Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurologic
• Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform